File this under “one step forward, two steps back.”
Just one week after Pfizer hoped to resume full production at a manufacturing plant with long-standing quality control problems, the drug maker has had to hit the pause button on some activities due to “additional maintenance” that needs to be performed, according to a company spokesman.
About the Author Reprints
